Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Risico op hepatitis C-virusinfectie geassocieerd met invasieve ziekenhuisingrepen
sep 2022 | Hepatitis